Abstract:Purpose/Objective: (64)Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) is a recently developed PET imaging marker for tumor hypoxia. However, its accuracy, reliability, and sensitivity have not been fully characterized in vivo. Also, activities from intravascular (64) Cu-ATSM that are not related to hypoxia, can also contribute to the PET signal. The purpose of this study is to validate its ability of hypoxia marker in animal mammary tumor model by comparing to immunostaining of a well-known hypoxia marker, EF5, and further characterize the dynamic uptake of 64Cu-ATSM in tumors using compartmental modeling to separate the intravascular signal contribution. Materials/Methods: R3230 mammary adenocarcinoma (R3230Ac) was used as tumor model and was implanted in the flank of Fisher344 rat. A dynamic (64) Cu-ATSM microPET scan was performed with a microPET R4 system. Tumor/muscle ratio and time activity curves were acquired from PET imaging. To validate the spatial correlation between (64) Cu-ATSM uptake and hypoxia area, EF5 and a vascular perfusion marker, Hoechst33342, were also administrated into the same animal during microPET scanning for subsequent histological imaging. Electronic autoradiography was conducted on tumor sections from the same animals. Images from microPET, autoradiography, EF5 immunostaining, Hoechst vascular perfusion, and H&E histology were aligned, and the distribution of (64) Cu-ATSM in the tumor was compared to the EF5/Hoechst fluorescent images. To further characterize the dynamic uptake of (64) Cu-ATSM in the tumor, a two-compartment model was used. In the model, the 64Cu-ATSM concentration is separated into an intravascular concentration (Cp) with vascular volume fraction (Vp) and extravascular concentration (Ce) with effective interstitial volume fraction (Ve). The transfer between the intra- and extra-vascular compartments is described by rate constant k(in) and k(out). After non-linear least square (NLLS) fitting to the dynamic scan data, the overall radioisotope signal in the tumor was separated into intravascular and extravascular components. Vascular volume fraction Vp and rate constant k were also obtained from the fitting. Results: The tumor-muscle ratio (T/M) of (64) Cu-ATSM measured by microPET in R3230Ac was 2.23 ± 0.11, indicating higher uptake in the tumor. The comparison between autoradiography and EF5/Hoechst staining showed high correlations between (64) Cu-ATSM uptake and hypoxia area (image correlation coefficient = 0.76). The area fraction of (64) Cu-ATSM uptake closely followed the area fraction of EF5 staining (0.24 ± 0.04 vs. 0.21 ± 0.03). The (64) Cu-ATSM uptake curves from PET imaging were fitted well by a two-compartment model for the R3230Ac tumor. The time courses of the intravascular and extravascular (64) Cu-ATSM signals were obtained from the NLLS fitting. Vascular volume fraction (Vp) and transfer constant (kin) were (2.50 ± 0.15) % and 0.045 ± 0.001 1/min, respectively. Conclusions: The distribution of (64) Cu-ATSM is closely correlated to tumor hypoxia in R3230Ac tumor. The uptake of (64)Cu-ATSM in R3230Ac can be also characterized by a compartmental model, which can effectively remove the intravascular radioisotope signal from the overall tissue signals, reflecting more accurately the tissue uptake and tumor hypoxia. The calculated tumor vascular volume fraction and transfer rate constant can be used to characterize the change of tumor hypoxia in the future study.

Monitoring Tumor Hypoxia Using F-18-Fmiso Pet And Pharmacokinetics Modeling After Photodynamic Therapy

Monitoring Tumor Hypoxia Using 18 F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy

18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice

Positron Emission Tomography Imaging of Tumor Hypoxia

Dual-Tracer Assessment of Dynamic Changes in Reoxygenation and Proliferation Decrease During Fractionated Radiotherapy in Murine Tumors.

Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats

Micro PET imaging of 18F-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model

In vivo Online label-free monitoring of heterogenous oxygen utilization during phototherapy with real-time ultrasound guided photoacoustic imaging

Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET

Self-reported and self-facilitated theranostic oxygen nano-economizer for precise and hypoxia alleviation-potentiated photodynamic therapy

Alteration of Hypoxia and Glucose Metabolism Measured by 18F-Fmiso and 18F-Fdg Micropet/Ct Imaging During Anti-Angiogenic Therapy

Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging.

Tissue pO2 distributions in xenograft tumors dynamically imaged by Cherenkov-excited phosphorescence during fractionated radiation therapy

The Application of Hypoxia Imaging with PET in Predicting Tumor Hypoxia and Guiding Clinical Therapy

Positron Emission Tomography Imaging Sheds New Light on Hypoxia and Antitumor Therapies

Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy Via Noninvasive Pet Molecular Imaging Strategies of Multifactorial Bioparameters

(64) Cu-Atsm Micropet Imaging Of Tumor Hypoxia In Mammary Tumor Model: Compartmental Modeling And Immunohistochemistry Analysis

The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth

A Comparative Study Of Noninvasive Hypoxia Imaging With F-18-Fluoroerythronitroimidazole And F-18-Fluoromisonidazole Pet/Ct In Patients With Lung Cancer

Comparison of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole Pet/Ct in Lung Cancer: A Pilot Clinical Study.

Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI